We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Plasma Serglycin Levels Evaluated for Diabetic Retinopathy Diagnosis

By LabMedica International staff writers
Posted on 04 Jan 2021
Print article
Image: The BD Biosciences FACS Vantage Flow Cytometer System (Photo courtesy of Hospital for Special Surgery).
Image: The BD Biosciences FACS Vantage Flow Cytometer System (Photo courtesy of Hospital for Special Surgery).
Diabetic retinopathy (DR), a microvascular complication caused by chronic diabetes mellitus (DM), is a significant threat to vision in adults, which may even lead to blindness and retinal detachment. The clinical symptoms of DR include fibrosis, capillary obstruction, neovascularization, and increased vascular permeability.

Serglycin (SRGN) is known as a hematopoietic cell granule proteoglycan, exerting its function in the formation of mast cell secretory granules and mediates the storage of various compounds in secretory vesicles. Studies have shown that SRGN is mainly expressed in normal hematopoietic cells, endothelial cells, uterine decidua, and embryonic stem cells.

Ophthalmologists at the Ningbo Eye Hospital (Ningbo, China) recruited,130 DR patients (64 proliferative diabetic retinopathy (PDR) patients and 66 non‐proliferative diabetic retinopathy (NPDR) patients, 55 type 2 diabetes mellitus (T2DM) patients, and 46 healthy controls, between December 2016 and March 2018.

The team measured the expressions of SRGN in plasma samples and cells were by qPCR analysis. Total RNA was extracted and then reverse‐transcribed into cDNA and amplified on an ABI PCR System (Applied Biosystems, Bedford, MA, USA). Total proteins were isolated from plasma samples and cells and the protein concentrations were determined by a Bicinchoninic Acid Protein method and separated by 10% SDS‐PAGE. The scientists also performed cell culture and transfection and CCK‐8 cell proliferation assays. Flow cytometric and cell apoptosis assay were also conducted using a FACS Vantage Flow Cytometer System (BD Biosciences, San Diego, CA, USA).

The investigators communicated that SRGN was dramatically upregulated in NPDR and PDR cases compared with healthy controls and T2DM patients; meanwhile, the expression of SRGN was further increased in the PDR group with regard to the NPDR group. Additionally, the ROC analysis demonstrated that SRGN could distinguish the DR cases from type 2 diabetes mellitus (T2DM) patients and healthy controls. In vitro high‐glucose treatment showed that the SRGN expressions were dramatically increased. The loss of SRGN could partially counteract the inhibition of human retinal endothelial cells (HREC) proliferation caused by high‐glucose stimulation. Meanwhile, SRGN knockdown could reverse the promotion of HREC apoptosis induced by high glucose as well.

The authors concluded that SRGN was significantly upregulated in the serum of DR patients, and after high‐glucose treatment, SRGN promoted the proliferation of human retinal pigment epithelial cells and inhibited the modulation of SRGN. At the same time, SRGN levels were able to screen DR patients from T2DM and healthy populations. The study was published on December 12, 2020 in the Journal of Clinical Laboratory Analysis.

Related Links:
Ningbo Eye Hospital
Applied Biosystems
BD Biosciences

Gold Supplier
Nucleic Acid Extractor
Gold Supplier
COVID-19 & Influenza A/B Test
FluCovid RT-PCR Kit
Influenza A/B Assay
Influenza A+B One Step Assay

Print article
BIOHIT  Healthcare OY



view channel
Image: Quidel Receives Amended FDA Emergency Use Authorization for New AI-Powered Sofia Q Rapid Antigen Test Device (Photo courtesy of Quidel Corporation)

Quidel Receives Amended FDA Emergency Use Authorization for New AI-Powered Sofia Q Rapid Antigen Test Device

Quidel Corporation (San Diego, CA, USA) has received an amended Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) allowing the company to market Sofia Q, its latest addition... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.